Biocon sees Rs 1,839 crore block deal driven by institutional buyers
A Rs 1,839 crore block trade in Biocon shares highlights strong institutional confidence in the pharmaceutical company’s debt reduction and biosimilars growth trajectory.
Institutional investors acquired Rs 1,839 crore worth of Biocon shares in a significant block deal, signaling robust market interest in the Indian pharmaceutical group. The transaction was executed at Rs 400 per share, drawing participation from a wide array of domestic and global financial institutions.
ICICI Prudential Mutual Fund emerged as the largest buyer, purchasing 1.84 crore shares for Rs 737 crore. HDFC Mutual Fund and Kotak Mahindra Mutual Fund followed closely, each acquiring 58.29 lakh shares for approximately Rs 233 crore.
SBI Mutual Fund bought 18.75 lakh shares valued at Rs 75 crore. Aditya Birla Sun Life Mutual Fund and ICICI Prudential Life Insurance Company each acquired 1.25 million shares worth Rs 50 crore. Additionally, Franklin Templeton Mutual Fund and Mirae Asset Mutual Fund each purchased 937,500 shares, valued at Rs 37.5 crore apiece.
The buy side also featured substantial global and specialized participation alongside other domestic institutions. International entities including Citigroup Global Markets Singapore, Goldman Sachs Bank Europe, Norges Bank, and the Ghisallo Master Fund participated in the trade. They were joined by domestic players such as UTI Mutual Fund, Axis Mutual Fund, Edelweiss Mutual Fund, Tata Mutual Fund, Motilal Oswal Mutual Fund, and 360 One Mutual Fund, as well as Bajaj Life Insurance and Axis Max Life Insurance.
This concentrated accumulation occurs as market participants closely monitor Biocon’s strategic priorities across its group businesses. The company operates in the biosimilars and research services sectors, areas drawing heightened scrutiny. Investors are specifically tracking the pharmaceutical group’s progress in reducing debt, expanding its biosimilars portfolio, and achieving margin recovery amid ongoing regulatory developments.
Such heavy institutional backing at the Rs 400 per share level provides a clear vote of confidence in the company’s underlying fundamentals. The broad coalition of mutual funds, life insurers, and foreign portfolio investors indicates a strong consensus on the valuation. It underscores a sustained institutional appetite for Indian healthcare assets positioned for long-term structural growth.
